Global study links seasonal flu vaccines to lower risk of H5N1 bird flu mortality

Analysis of nearly two decades of data suggests that widely available influenza vaccines containing neuraminidase N1 may cut death rates from avian influenza H5N1, offering some interim protection while targeted vaccines remain in development

Emerging evidence has suggested that seasonal influenza vaccines which are already in use routinely worldwide may offer partial protection against the highly pathogenic avian influenza A (H5N1) virus which has continued to spread between species and has raised concern about pandemic potential.

In a recent study an international research team led by National Taiwan University, Taipei, Taiwan, in collaboration with the University of South Florida, Tampa, USA, has reported that certain seasonal influenza vaccines could reduce mortality risk associated with H5N1 infection. The findings have pointed to a pragmatic strategy for pandemic preparedness at a time when specific H5N1 vaccines may not be available at sufficient scale during the early phase of a widespread outbreak.

The investigators conducted a systematic review and meta-analysis that drew on nearly 20 years of experimental data from 35 controlled studies. Their analysis focused on the presence of neuraminidase subtype N1, a viral surface protein included in some seasonal influenza vaccine formulations. Across animal models, vaccines that contained this component reduced H5N1-related mortality by approximately 73 per cent compared with unvaccinated controls.

This level of protection approached that observed in some H5N1-targeted vaccines that failed to induce robust immune responses and fell only modestly below that seen in more immunogenic H5N1-specific candidates. By contrast, seasonal influenza vaccines that lacked the N1 component conferred little to no measurable protection, which indicated that specific antigenic elements within established vaccines may exert a disproportionate influence on cross-protection against emerging strains.

“This work suggests that we may be underestimating the broader protective value of seasonal influenza vaccines,” said Dr. Chi-Tai Fang, a professor of infectious diseases epidemiology at the National Taiwan University hospital and senior author of the study.

“While they [have not been] designed to target H5N1, certain components appear to activate immune responses that can reduce the severity of infection. In a real-world setting, that kind of partial protection could translate into [many] lives saved while more specific vaccines are being developed and distributed,” he said.

The study has also highlighted the operational significance of timing in outbreak response. Seasonal influenza vaccines are already manufactured, licensed by relevant regulatory bodies and distributed at scale, which contrasts with the months that it typically requires to design, test and deploy strain-specific pandemic vaccines.

“In a pandemic scenario, timing is everything,” said Dr. Sten Vermund, the dean of the USF Health College of Public Health and chief medical officer of the Global Virus Network.

“[There is] often … a critical gap between the emergence of a novel virus and the availability of a targeted vaccine.

“Our findings suggest that [the current] seasonal flu vaccination, something already widely available, could help reduce severe outcomes during that window. That is a meaningful advantage when every week matters,” Vermund said.

A notable aspect of the findings concerns the mechanism of protection. Standard serological assays failed to detect antibodies against H5N1 in vaccinated subjects, which would traditionally indicate a lack of immunity. However, the observed reduction in mortality suggests that alternative immune pathways are involved.

The authors have proposed that cross-reactive cellular immune responses – rather than antibody-mediated neutralisation alone – may underpin this effect. Such responses are not routinely captured in conventional laboratory tests which may lead to the underestimation of functional immunity already in the community.

The study has arrived at a time when H5N1 has continued to circulate among avian populations and has crossed into a growing number of mammalian hosts, with sporadic human infections reported. Vaccine availability has remained limited in many regions which would leave health systems exposed during the earliest phase of any potential zoonotic spillover events.

Although the researchers have emphasised that their findings derive from animal models and require validation in human populations, they have identified a clear direction for future work. Specifically, further investigation is needed to determine how prior exposure to seasonal influenza vaccination may shape clinical outcomes following infection with emerging influenza strains.

In practical terms, the results have suggested that broader uptake of seasonal influenza vaccines could offer an interim public health measure. By reducing mortality, easing pressure on healthcare systems and potentially moderating disease severity, such an approach could provide valuable time for the development and deployment of strain-specific countermeasures.

For further reading please visit: 10.1080/22221751.2026.2654278